Lipitor Lawsuit News: Judicial Panel Denies Consolidation of Federal Cases, Rottenstein Law Group LLP Reports
The firm is currently offering Lipitor lawsuit evaluations to women who have suffered from serious alleged adverse Lipitor side effects.
(PRWEB) September 11, 2013
A federal panel of judges, after three months of deliberation, denied a motion for consolidation of Lipitor-induced Type 2 diabetes cases, according to an Aug. 8 panel order.* The Rottenstein Law Group LLP, a Lipitor law firm, offers an explanation of what the decision means for those looking to file Lipitor lawsuits.
The U.S. Judicial Panel on Multidistrict Litigation oversees consolidations of federal lawsuits. In its order, the JPML wrote that, “in particular, almost half of the actions currently comprising this litigation are pending in a single district—the District of South Carolina, and many of the actions involve common plaintiffs’ counsel. The South Carolina actions already are proceeding in a coordinated fashion before one judge.”
In the order, the JPML also indicated that Pfizer was willing to coordinate with the plaintiffs with regard to the consolidation of pretrial proceedings such as common discovery, which is the primary purpose of a multidistrict litigation. Therefore, the JPML denied the motion to create an MDL, according to the order.
Read full story at PRWeb.com: Lipitor Lawsuit News: Judicial Panel Denies Consolidation of Federal Cases, Rottenstein Law Group LLP Reports